Warning: array_shift() [function.array-shift]: The argument should be an array in /htdocs/public/www/config/ecran_securite.php on line 245
Evidence of Clonazepam abuse liability : results of the tools developed by the French CEIP network - addictovigilance.fr

Accueil du site > Articles publiés > 2011 > Evidence of Clonazepam abuse liability : results of the tools developed by (...)

Evidence of Clonazepam abuse liability : results of the tools developed by the French CEIP network

Frauger et al., Fundamental & clinical pharmacology, 2011
  • Titre traduit : Mise en évidence du détournement d’usage du clonazépam : résultats des outils développés par le réseau français des CEIP
  • Auteurs : E. Frauger, V. Pauly, V. Pradel, F. Rouby, J. Arditti, X. Thirion, M. Lapeyre Mestre, J. Micallef
  • Résumé : Recent observations suggest the existence of clonazepam abuse. To determine its importance in France, a quantitative and systematic synthesis of all clonazepam data of several epidemiological tools of the Centers for Evaluation and Information on Pharmacodependence (CEIP) network has been performed in comparison with data on others benzodiazepines (BZD). Data on clonazepam and other BZD have been analysed from different epidemiological tools : OSIAP survey that identifies drugs obtained by means of falsified prescriptions, Observation of Illegal Drugs and Misuse of Psychotropic Medications (OPPIDUM) survey that describes modalities of use and data from regional French health reimbursement system. In OSIAP survey, the proportion of clonazepam falsified prescriptions among all BZD falsified prescriptions increased. During the 2006 OPPIDUM survey, the analysis of the BZD modalities of use highlights clonazepam abuse liability (for example 23% of illegal acquisition), in second rank after flunitrazepam. Studies based on data from the French health reimbursed system show that 1.5% of subjects with clonazepam dispensing had a deviant behaviour. Among BZD, clonazepam has the second most important doctor-shopping indicator (3%) after flunitrazepam. All these data provide some arguments in favour of clonazepam abuse liability in real life and the necessity to reinforce its monitoring.
  • Référence : Frauger et al., Fundamental & clinical pharmacology, 2011 Oct ;25(5):633-41
  • Liens :
    • Résumé sur PubMed
    • Texte intégral sur addictovigilance.fr + (accès restreint aux seuls Centres d’Addictovigilance)

Dans la même rubrique